

ASX ANNOUNCEMENT

Pharma Executive Appointed to Recce Board

- **Leading global pharmaceutical executive appointed to Recce's Board**

Perth, Western Australia, 27 May 2016 – Recce Ltd (ASX: RCE) the developer of a new class of patented drugs targeted at antibiotic and anti-cancer human applications, is pleased to announce the appointment of Bernadette Murdoch as an Independent Non-Executive Director.

Bernadette Murdoch is currently Head of Corporate Affairs and Communications, Australasia for Glaxo Smith Kline (GSK). Her understanding of the pharmaceutical industry and experience in scientific communications will be an asset to the Board as Recce approaches clinical human trials for RECCE® 327.

Bernadette has been employed in pharmaceutical Public Relations, Communications and Corporate Affairs as an increasingly senior manager throughout UK, Europe, Middle-East and Africa. Earlier, after graduate qualifications in Public Relations, Bernadette was an associate within global Burson-Marsteller, and later in related consulting roles advised prominent clients CSL, Melbourne Water, Motorola, Australian Telecommunications Association and GSK.

Consistently, Bernadette has won public and corporate awards as she has managed key media and public campaigns, introducing new products relating to children's health, women's health and male diseases.

Dr Graham Melrose, Executive Chairman, and his fellow directors are very pleased to welcome Ms Bernadette Murdoch.

Dr Graham Melrose, Executive Chairman commented "This appointment, following on the recent appointment of Dr Dominic Barnes to the Board – Recce is now outstandingly structured and positioned to target its technology against the global health threat from superbugs".

For further information please visit www.recce.com.au or contact:

Investor Relations

Peter Williams
CFO & Company Secretary
Recce Ltd
Tel: +61 8 9253 9800

Media Communication

Karen Oswald - karen.oswald@markocommunications.com.au
Gary Buchholz – gary@markocommunications.com.au
Marko Communications
Tel: +61 423 602 353

About Recce Ltd

Recce Ltd (ASX: RCE) is a world-leader in synthetic-polymer antibiotics. The RECCE® antibiotics have been synthesized by an extremely economic method.

RECCE® antibiotics have shown in laboratory tests that they have continued activity against bacteria, including superbugs, even after repeated use.



ASX: RCE

Head Office - Perth Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9253 9800 **F** +61 (8) 9253 9899
Sydney Office Level 36, 1 Macquarie Place, Gateway Tower, SYDNEY NSW 2000 **T** +61 (2) 8075 4707
Washington Office 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

Recce is positioned to achieve milestones in both pre-clinical trials for FDA purposes, and the development of the manufacture of RECCE® 327 antibiotic.

The discovery of RECCE® 327's capabilities against cancer (as well as bacteria-superbugs) has greatly increased the value of the Company's technology, especially in view of synergism between the anti-cancer and antibiotic properties.

Recce has granted patents in Australia, United States, Europe, Japan and China – giving it legal monopolies and potential financial returns from manufacture and distribution in some 80% of the world's pharmaceutical markets.

To receive the latest information on Recce - [Subscribe here](#)

